• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌/睾丸抗原OY-TES-1的血清免疫反应性及其在胶质瘤中的组织表达。

Serum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma.

作者信息

Li Xisheng, Yan Jun, Fan Rong, Luo Bin, Zhang Qingmei, Lin Yongda, Zhou Sufang, Luo Guorong, Xie Xiaoxun, Xiao Shaowen

机构信息

Department of Neurosurgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.

Department of Histology and Embryology, School of Pre-Clinical Medicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.

出版信息

Oncol Lett. 2017 May;13(5):3080-3086. doi: 10.3892/ol.2017.5799. Epub 2017 Mar 3.

DOI:10.3892/ol.2017.5799
PMID:28529561
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5431674/
Abstract

OY-TES-1 is a member of the cancer/testis antigen family that is expressed in healthy testis tissue and certain types of cancerous tissue. The present study aimed to analyze the expression pattern of OY-TES-1 and serum anti-OY-TES-1 antibody concentration in patients with glioma. OY-TES-1 mRNA was detected in 28/36 (78%) of glioma cases using conventional reverse transcription polymerase chain reaction (RT-PCR) analysis. RT-quantitative-PCR revealed that OY-TES-1 was expressed at a higher level in glioma tissues compared with normal adult tissues (with the exception of testis tissue). Anti-OY-TES-1 antibodies were present in the serum of 5/36 (14%) of patients with glioma, but absent in all the serum samples from 107 healthy donors. Immunohistochemical analysis demonstrated that OY-TES-1 protein was expressed in all glioma tissues from patients with anti-OY-TES-1 antibody seropositivity. These results suggest that OY-TES-1 is a novel candidate for glioma immunotherapy.

摘要

OY-TES-1是癌症/睾丸抗原家族的成员,在健康的睾丸组织和某些类型的癌组织中表达。本研究旨在分析胶质瘤患者中OY-TES-1的表达模式及血清抗OY-TES-1抗体浓度。使用传统逆转录聚合酶链反应(RT-PCR)分析在36例胶质瘤病例中的28例(78%)检测到OY-TES-1 mRNA。逆转录定量PCR显示,与正常成人组织(睾丸组织除外)相比,OY-TES-1在胶质瘤组织中表达水平更高。36例胶质瘤患者中有5例(14%)血清中存在抗OY-TES-1抗体,但107名健康供者的所有血清样本中均未检测到。免疫组织化学分析表明,抗OY-TES-1抗体血清阳性患者的所有胶质瘤组织中均表达OY-TES-1蛋白。这些结果表明,OY-TES-1是胶质瘤免疫治疗的一个新候选物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7778/5431674/8faa916e29f3/ol-13-05-3080-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7778/5431674/fa1cd8cf01cd/ol-13-05-3080-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7778/5431674/fc26566bc945/ol-13-05-3080-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7778/5431674/8faa916e29f3/ol-13-05-3080-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7778/5431674/fa1cd8cf01cd/ol-13-05-3080-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7778/5431674/fc26566bc945/ol-13-05-3080-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7778/5431674/8faa916e29f3/ol-13-05-3080-g02.jpg

相似文献

1
Serum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma.癌/睾丸抗原OY-TES-1的血清免疫反应性及其在胶质瘤中的组织表达。
Oncol Lett. 2017 May;13(5):3080-3086. doi: 10.3892/ol.2017.5799. Epub 2017 Mar 3.
2
Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma.癌-睾丸抗原OY-TES-1在肝细胞癌中的表达及免疫原性
Curr Med Sci. 2020 Aug;40(4):719-728. doi: 10.1007/s11596-020-2241-x. Epub 2020 Aug 29.
3
Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters.癌睾丸抗原OY-TES-1在结直肠癌中的表达及血清免疫原性:其与临床病理参数的关系
Int J Clin Exp Pathol. 2013 Nov 15;6(12):2835-45. eCollection 2013.
4
OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer.OY-TES-1在上皮性卵巢癌中的表达及血清免疫反应性
Int J Oncol. 2006 Oct;29(4):903-10.
5
Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen.鉴定前顶体蛋白酶结合蛋白sp32前体作为一种人类癌胚抗原。
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3282-7. doi: 10.1073/pnas.041625098.
6
Cancer testis antigen OY-TES-1: analysis of protein expression in ovarian cancer with tissue microarrays.癌睾丸抗原OY-TES-1:利用组织芯片分析其在卵巢癌中的蛋白表达
Eur J Gynaecol Oncol. 2015;36(3):298-303.
7
Knockdown of OY-TES-1 by RNAi causes cell cycle arrest and migration decrease in bone marrow-derived mesenchymal stem cells.RNAi 敲低 OY-TES-1 导致骨髓间充质干细胞的细胞周期停滞和迁移减少。
Cell Biol Int. 2012 Oct 1;36(10):917-22. doi: 10.1042/CBI20120037.
8
Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro.癌胚抗原OY-TES-1的下调减弱了肝癌细胞在体外的恶性行为。
Int J Clin Exp Pathol. 2015 Jul 1;8(7):7786-97. eCollection 2015.
9
Immunohistochemistry Study of OY-TES-1 Location in Fetal and Adult Human Tissues.免疫组织化学研究 OY-TES-1 在胎儿和成人人体组织中的定位。
J Healthc Eng. 2022 Apr 13;2022:7052830. doi: 10.1155/2022/7052830. eCollection 2022.
10
Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T-cells.鉴定一种被细胞毒性T细胞识别的HLA - A24限制性OY - TES - 1表位。
Microbiol Immunol. 2005;49(11):1009-16. doi: 10.1111/j.1348-0421.2005.tb03688.x.

引用本文的文献

1
Unveiling the significance of cancer-testis antigens and their implications for immunotherapy in glioma.揭示癌症睾丸抗原的重要性及其在神经胶质瘤免疫治疗中的意义。
Discov Oncol. 2024 Oct 29;15(1):602. doi: 10.1007/s12672-024-01449-4.
2
Fusion of NY-ESO-1 epitope with heat shock protein 70 enhances its induced immune responses and antitumor activity against glioma .NY-ESO-1表位与热休克蛋白70的融合增强了其诱导的免疫反应和对神经胶质瘤的抗肿瘤活性。
Transl Cancer Res. 2024 Jan 31;13(1):191-201. doi: 10.21037/tcr-23-1476. Epub 2024 Jan 19.
3
Prediction and identification of HLA-A*0201-restricted epitopes from cancer testis antigen CT23.

本文引用的文献

1
Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro.癌胚抗原OY-TES-1的下调减弱了肝癌细胞在体外的恶性行为。
Int J Clin Exp Pathol. 2015 Jul 1;8(7):7786-97. eCollection 2015.
2
Cancer testis antigen OY-TES-1: analysis of protein expression in ovarian cancer with tissue microarrays.癌睾丸抗原OY-TES-1:利用组织芯片分析其在卵巢癌中的蛋白表达
Eur J Gynaecol Oncol. 2015;36(3):298-303.
3
Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor.
预测和鉴定癌症睾丸抗原 CT23 中 HLA-A*0201 限制性表位。
Hum Vaccin Immunother. 2023 Dec 15;19(3):2293299. doi: 10.1080/21645515.2023.2293299.
4
Expression and clinical importance of a newly discovered alternative splice variant of the gene for acrosin binding protein found in human brain tumors.在人脑肿瘤中发现的一种新的顶体蛋白酶结合蛋白基因可变剪接变体的表达及其临床意义。
Asian Biomed (Res Rev News). 2020 Dec 31;14(6):243-252. doi: 10.1515/abm-2020-0033. eCollection 2020 Dec.
5
Alternative splicing of acrosin binding protein RNA transcript and its potential contributions to innovative cancer therapy.顶体素结合蛋白RNA转录本的可变剪接及其对创新癌症治疗的潜在贡献。
Asian Biomed (Res Rev News). 2020 Dec 31;14(6):215-216. doi: 10.1515/abm-2020-0031. eCollection 2020 Dec.
6
FMR1NB Involved in Glioma Tumorigenesis Is a Promising Target for Prognosis and Therapy.FMR1NB 参与脑肿瘤发生,是预后和治疗的有希望的靶点。
Curr Med Sci. 2022 Aug;42(4):803-816. doi: 10.1007/s11596-022-2586-4. Epub 2022 Jul 11.
7
Immunohistochemistry Study of OY-TES-1 Location in Fetal and Adult Human Tissues.免疫组织化学研究 OY-TES-1 在胎儿和成人人体组织中的定位。
J Healthc Eng. 2022 Apr 13;2022:7052830. doi: 10.1155/2022/7052830. eCollection 2022.
8
Hijacking Sexual Immuno-Privilege in GBM-An Immuno-Evasion Strategy.在 GBM 中劫持性免疫特权——一种免疫逃避策略。
Int J Mol Sci. 2021 Oct 12;22(20):10983. doi: 10.3390/ijms222010983.
9
Cancer-testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis.卵巢癌中癌症-睾丸抗原 ACRBP 的表达和血清免疫反应性与其预后的关系。
Immun Inflamm Dis. 2021 Dec;9(4):1759-1770. doi: 10.1002/iid3.534. Epub 2021 Sep 16.
10
Combined treatment with epigenetic agents enhances anti-tumor activity of T cells by upregulating the ACRBP expression in hepatocellular carcinoma.表观遗传药物联合治疗通过上调肝细胞癌中ACRBP的表达增强T细胞的抗肿瘤活性。
Am J Transl Res. 2021 Jul 15;13(7):7591-7609. eCollection 2021.
SUMO 化的热休克蛋白 90 是一种常染色体显性遗传的浆细胞发育异常危险因素。
J Clin Invest. 2015 May;125(5):2179. doi: 10.1172/JCI82091. Epub 2015 May 1.
4
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.CBTRUS统计报告:2007 - 2011年在美国诊断出的原发性脑和中枢神经系统肿瘤
Neuro Oncol. 2014 Oct;16 Suppl 4(Suppl 4):iv1-63. doi: 10.1093/neuonc/nou223.
5
High expression and frequently humoral immune response of melanoma-associated antigen D4 in glioma.黑色素瘤相关抗原D4在胶质瘤中的高表达及频繁的体液免疫反应
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2350-60. eCollection 2014.
6
Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers.肿瘤亚型特异性的肿瘤睾丸抗原作为癌症的潜在生物标志物和免疫治疗靶点。
Cancer Immunol Res. 2014 Apr;2(4):371-9. doi: 10.1158/2326-6066.CIR-13-0088. Epub 2013 Nov 25.
7
Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters.癌睾丸抗原OY-TES-1在结直肠癌中的表达及血清免疫原性:其与临床病理参数的关系
Int J Clin Exp Pathol. 2013 Nov 15;6(12):2835-45. eCollection 2013.
8
Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results.放疗联合辅助替莫唑胺治疗胶质母细胞瘤:日本单机构研究结果。
PLoS One. 2013 Nov 12;8(11):e78943. doi: 10.1371/journal.pone.0078943. eCollection 2013.
9
Expression of cancer/testis antigens is correlated with improved survival in glioblastoma.癌胚抗原的表达与胶质母细胞瘤患者生存率的提高相关。
Oncotarget. 2013 Apr;4(4):636-46. doi: 10.18632/oncotarget.950.
10
Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution.中国脑胶质瘤患者的管理和生存率(2004-2010 年):来自单一机构的回顾性研究。
J Neurooncol. 2013 Jun;113(2):259-66. doi: 10.1007/s11060-013-1103-9. Epub 2013 Mar 13.